OKUR (OnKure Therapeutics) ROE % Adjusted to Book Value: -54.79% (As of Mar. 2026)


OKUR OnKure Therapeutics Inc OKUR
14 GF Score
Price $4.47
! 2 Warning Signs
View Full Analysis

What is OnKure Therapeutics ROE % Adjusted to Book Value?

OnKure Therapeutics OKUR -2.19% 14 ROE % Adjusted to Book Value is -54.79% as of Mar. 2026. GuruFocus rates OKUR with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

OnKure Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -50.41%. OnKure Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 0.92. OnKure Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -54.79%.

OnKure Therapeutics ROE % Adjusted to Book Value Related Terms

OnKure Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for OnKure Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OnKure Therapeutics ROE % Adjusted to Book Value Chart

OnKure Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 -4,778.77 -104.77

OnKure Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -102.36 -177.88 -145.23 -124.08 -54.79

OKUR vs ANTX, PLX, KRRO: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, OnKure Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OnKure Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OnKure Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where OnKure Therapeutics's ROE % Adjusted to Book Value falls into.


OKUR
14GF Score
OnKure Therapeutics Inc OKUR
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OnKure Therapeutics ROE % Adjusted to Book Value Calculation

OnKure Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-74.39% / 0.71
=-104.77%

OnKure Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-50.41% / 0.92
=-54.79%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -54.79% mean?
OnKure Therapeutics (OKUR) has a ROE % Adjusted to Book Value of -54.79% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on OnKure Therapeutics and its competitors.
Is OnKure Therapeutics' ROE % Adjusted to Book Value too high?
OnKure Therapeutics' current ROE % Adjusted to Book Value is -54.79%. Overall, OnKure Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does OnKure Therapeutics' ROE % Adjusted to Book Value compare to ANTX and PLX?
OnKure Therapeutics' ROE % Adjusted to Book Value of -54.79% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on OnKure Therapeutics and its competitors. OnKure Therapeutics's current ROE % Adjusted to Book Value is -54.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OnKure Therapeutics stock overvalued right now?
OnKure Therapeutics (OKUR) has a current ROE % Adjusted to Book Value of -54.79%. The current ROE % Adjusted to Book Value is -54.79%. OnKure Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For OnKure Therapeutics (OKUR), the current ROE % Adjusted to Book Value is -54.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OnKure Therapeutics Business Description

Address 6707 Winchester Circle, Suite 400, Boulder, CO, USA, 80301
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3K?. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
14GF Score

Get the complete analysis for OKUR

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.47
Price